Jun 15, 2025, 14:04
Christopher Williams: New Meta-Analysis on Neoadjuvant Chemotherapy in Colon Cancer from Mayo Clinic
Christopher Williams, Senior Clinical Research Fellow at University of Leeds, shared a post on LinkedIn:
“Neoadjuvant chemotherapy in loc adv colon cancer
New meta-analysis from Mayo Clinic Healthcare researchers.
Includes FOxTROT, OPTICAL, PRODIGE-22 and NeoCol.
Neoadjuvant chemo vs Straight-to-surgery:
5yr OS 81.4% vs 77.8%
5yr DFS 79.2% vs 73.7%
R1 resections 4.1% vs 6.3%.”
Title: Oncological Outcomes of Neoadjuvant Chemotherapy Versus Upfront Surgery in Locally Advanced Colon Cancer: A Systematic Review, Meta-Analysis, and Sequential Analysis
Authors: Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Francesco Brucchi, Giulio Mari, Isacco Montroni, Eric J. Dozois, David W. Larson
More posts featuring Colon Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 11:38